Farmacias similares begins expansion to japan

The mexican pharmacy chain farmacias similares, led by víctor gonzález herrera, has started its expansion strategy to japan through digital marketing and brand adaptation. With 10,000 branches in latin america, the company aims to replicate its generic medicines model in a highly regulated market. This move marks a milestone in its internationalization beyond the american continent.

Farmacias similares, latin america's largest pharmacy chain with 10,000 branches, has solidified its business model focused on generic medicines and adjacent medical consultations. This strategy has driven its growth in mexico and enabled prior explorations in central america.

Now, under the leadership of víctor gonzález herrera, the company is projecting its entry into the japanese market through a focus on digital marketing and social networks. According to the 'de jefes' column published on february 16, 2026, in el financiero, the firm will adapt its corporate identity and emblematic characters, such as doctor simi, under a local japanese aesthetic to connect with asian consumers.

"This growth phase seeks to diversify the group's income and validate the scalability of its generic medicines business model in markets with high regulation and technological demand," the column states.

The japanese pharmaceutical market poses significant challenges, with a highly regulated health system and strong presence of national pharmaceuticals. To enter, farmacias similares would need to comply with regulations from the pharmaceuticals and medical devices agency (pmda) and adapt to the pricing structure of the japanese health system. Sector experts emphasize the need for local alliances, rigorous sanitary certifications, and adaptation to advanced technological standards, given the high entry barriers for imported generic medicines and complex sanitary norms.

This incursion represents an effort to position the brand and the recognition of doctor simi in one of the world's most robust economies, replicating operational success outside the americas.

相关文章

The Chamber of Deputies approved on Monday (2) the bill allowing medicine sales in pharmacies installed inside supermarkets, with rules for physical separation and pharmacist presence. The text, heading to presidential sanction, aims to facilitate access to medicines, especially in remote areas, but faces opposition from some deputies over public health risks.

由 AI 报道

周五东京早盘,日本制药公司股价下跌,此前美国总统唐纳德·特朗普推出提供折扣处方药的网站。住友制药、中外制药和武田制药等主要企业股价下滑,拖累整个制药板块整体表现。特朗普周四宣布与全球16家最大药企达成协议,以最惠国价格换取关税豁免。

2025年,中国药企与全球制药公司签署了157项外部授权协议,总价值达1357亿美元,较2024年的94项交易和519亿美元大幅增长。国家药品监督管理局(NMPA)上周发布的数据显示,此类交易数量和价值均创历史新高,推动了香港和内地上市公司与国际巨头的多笔数十亿美元协议。

由 AI 报道

三家主要日本便利店运营商报告2025年3月至11月期间集团经营利润增长。Seven & I Holdings、Lawson和FamilyMart均通过各种策略实现了利润增长。

 

 

 

此网站使用 cookie

我们使用 cookie 进行分析以改进我们的网站。阅读我们的 隐私政策 以获取更多信息。
拒绝